Non-metastatic castration-resistant prostate cancer: management recommendations

Introduction and objective: Survival and quality of life (QoL) of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) deteriorate significantly when they develop metastases. New generation antiandrogens (apalutamide, enzalutamide and darolutamide) can prolong metastasis-free survival (MFS) and overall survival (OS) in these patients, maintaining their QoL. Material and methods: After the performance of a systematic review of the literature, a scientific committee reached a consensus on simple and practical recommendations to consolidate and improve the management of patients with nmCRPC in urology consultations. Results: Recommendations are made on the frequency of PSA determination and imaging tests in patients with nmCRPC. The importance of co-morbidities in patients with nmCRPC is also highlighted, and recommendations are also made on functional and QoL assessment that can be carried out during urology consultations. The efficacy, safety, and effects on QoL of new generation antiandrogens are reviewed. Conclusions: To evaluate treatment of patients with nmCRPC, it is necessary to consider co morbidities and QoL, in addition to age. New generation antiandrogens are a safe and effective treatment option for patients with nmCRPC. The recommendations of this review can be helpful in optimizing the management of nmCRPC patients in urology consultations. (c) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.

Automated summary

This study provides recommendations for the management of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) based on a systematic review of the literature and consensus from a scientific committee. The recommendations cover various aspects including disease assessment, treatment options, and quality of life evaluation.